A5 Laboratories (OTCBB: AFLB) is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
AFLB Investor Highlights
Announced that it has reached an agreement to provide full CRO and development services to Neolabs of Concord, Ontario.
Announced that it has completed the acquisition of the Contract Research (CRO) and Interferon production technology. The company plans to immediately secure the intellectual property related to the interferon production technology as well as complete its plans for pilot scale production and commercialization of interferon products for veterinary and human applications.
To learn more about AFLB visit http://www.smallcapreview.com/featurestock.htm
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview has been compensated five thousand dollars for its efforts with regards to A5 Laboratories by a third party AWT.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/.
